MEMORIAL HOSPITAL FOR CANCER AND ALL

Type: Teaching hospital
Where: Middletown, NJ
Medicare CCN: 330154
Received: $25,439,492 in 759 records, 2019 ($685,332 general, $24,754,160 research)
Source: CMS Open Payments search ↗

By year

Program year	Kind	Records	Amount
2019	General payment	15	$685,332
2019	Research payment	744	$24,754,160

By company

Company	Records	Amount	Years
AstraZeneca Pharmaceuticals LP	36	$11,465,253	2019
PFIZER INC.	52	$5,669,741	2019
Merck Sharp & Dohme LLC	26	$2,157,350	2019
Bayer Healthcare Pharmaceuticals Inc.	33	$1,435,158	2019
AstraZeneca UK Limited	8	$1,062,204	2019
Eisai Inc.	441	$686,858	2019
E.R. Squibb & Sons, L.L.C.	1	$600,000	2019
TESARO, Inc.	14	$518,521	2019
EMD Serono, Inc.	68	$423,038	2019
GE Global Research an unincorporated business of GE Company	9	$236,181	2019
Adaptive Biotechnologies Corporation	2	$199,743	2019
MEDIVATION LLC.	6	$196,326	2019
Pharmacyclics LLC, an AbbVie Company	1	$169,215	2019
Plexxikon Inc.	3	$125,718	2019
Amgen Inc.	8	$98,764	2019
Boehringer Ingelheim International GmbH	4	$62,030	2019
GlaxoSmithKline, LLC.	2	$56,724	2019
Astellas Pharma Global Development	4	$52,520	2019
Biogen, Inc.	1	$51,170	2019
VENTANA MEDICAL SYSTEMS, INC.	12	$42,828	2019
Janssen Research & Development, LLC	10	$29,572	2019
Biocompatibles UK Ltd	1	$20,952	2019
Philips North America LLC	1	$19,200	2019
Boehringer Ingelheim Pharma GmbH & Co.KG	1	$15,282	2019
Boehringer Ingelheim Pharmaceuticals, Inc.	2	$14,028	2019
Rivanna Medical, Inc	2	$13,932	2019
Cardinal Health 414 LLC	1	$10,000	2019
Boehringer Ingelheim Limited	3	$3,844	2019
Olympus America Inc.	6	$3,066	2019
Edwards Lifesciences Corporation	1	$266	2019

By nature of payment

Nature	Records	Amount
Research payment	744	$24,754,160
Grant	7	$657,000
Compensation for services other than consulting, including serving as faculty or as a speaker at a v	1	$25,000
Gift	6	$3,066
Education	1	$266

Records

Date	Company	Amount	Nature	Form	Product	Study	Year
2019-12-31	AstraZeneca UK Limited	$34,705	Research payment	In-kind items and services		A Phase I Open-Label Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of Ascending Dose	2019
2019-12-31	Philips North America LLC	$19,200	Research payment	Cash or cash equivalent	Ingenia 3 0T R5 Device, Devices		2019
2019-12-31	AstraZeneca Pharmaceuticals LP	$8,706	Research payment	In-kind items and services		A Multi arm Phase Ib Open Label, Multicentre Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary An	2019
2019-12-31	AstraZeneca Pharmaceuticals LP	$5,751	Research payment	In-kind items and services		A Phase I, Open Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumou	2019
2019-12-31	AstraZeneca Pharmaceuticals LP	$833	Research payment	In-kind items and services		A Modular Phase I Open-Label Multicentre Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Anti-t	2019
2019-12-31	AstraZeneca Pharmaceuticals LP	$683	Research payment	In-kind items and services	LYNPARZA Drug, Oncology	A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Pati	2019
2019-12-31	Edwards Lifesciences Corporation	$266	Education	In-kind items and services	EV1000 Clinical Platform Device, Minimally Invasive Hemodynamic Monitoring		2019
2019-12-31	AstraZeneca UK Limited	$161	Research payment	In-kind items and services	LYNPARZA Drug, Oncology	Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy	2019
2019-12-31	EMD Serono, Inc.	$69	Research payment	Cash or cash equivalent	EMD 1214063 Biological, Oncology	MS200095-0022	2019
2019-12-31	EMD Serono, Inc.	$69	Research payment	Cash or cash equivalent	EMD 1214063 Biological, Oncology	MS200095-0022	2019
2019-12-31	EMD Serono, Inc.	$69	Research payment	Cash or cash equivalent	EMD 1214063 Biological, Oncology	MS200095-0022	2019
2019-12-31	AstraZeneca UK Limited	$46	Research payment	In-kind items and services	IMFINZI Drug, Oncology	A Phase II Non comparative Open Label Multi centre International Study of MEDI4736 in Patients With Locally Advanced or	2019
2019-12-31	AstraZeneca Pharmaceuticals LP	$4	Research payment	In-kind items and services	LYNPARZA Drug, Oncology	This is a non randomized open label study to assess olaparib tablets as a treatment for subjects with different homologo	2019
2019-12-30	TESARO, Inc.	$34,568	Research payment	In-kind items and services	ZEJULA Drug, ONCOLOGY	A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENT	2019
2019-12-30	Bayer Healthcare Pharmaceuticals Inc.	$6,750	Research payment	Cash or cash equivalent	Non-Covered	Ph III Copanlisib+Rituximab in relapsed iNHL	2019
2019-12-25	GE Global Research an unincorporated business of GE Company	$12,557	Research payment	Cash or cash equivalent			2019
2019-12-24	Amgen Inc.	$31,103	Research payment	Cash or cash equivalent		AMG 757_SCLC_20160323	2019
2019-12-23	Bayer Healthcare Pharmaceuticals Inc.	$422	Research payment	Cash or cash equivalent	Nexavar Drug, Oncology	Investigator Fees or Payments	2019
2019-12-21	Amgen Inc.	$3,819	Research payment	Cash or cash equivalent		AMG 420_Non-Randomized Open-Label Expansion_Multiple Myeloma_20160370.	2019
2019-12-16	AstraZeneca Pharmaceuticals LP	$188,349	Research payment	Cash or cash equivalent	IMFINZI Drug, Oncology	Phase II Randomized Trial of Durvalumab MEDI4736 Anti PD L1 Antibody with or without Tremelimumab in Patients with Persi	2019
2019-12-16	PFIZER INC.	$124,000	Research payment	In-kind items and services	VIZIMPRO Drug, ONCOLOGY	PHASE 1 STUDY OF COMBINATION DACOMITINIB AND OSIMERTINIB FOR PATIENTS WITH METASTATIC EGFR MUTANT LUNG CANCERS	2019
2019-12-16	PFIZER INC.	$102,060	Research payment	In-kind items and services	TALZENNA Drug, ONCOLOGY	FULL TALAZOPARIB AND AVELUMAB IN GENOMICALLY DEFINED METASTATIC RENAL CELL CARCINOMA	2019
2019-12-16	EMD Serono, Inc.	$43,740	Research payment	Cash or cash equivalent	EMD 1214063 Biological, Oncology	MS200095-0022	2019
2019-12-16	EMD Serono, Inc.	$38,741	Research payment	Cash or cash equivalent	EMD 1214063 Biological, Oncology	MS200095-0022	2019
2019-12-16	PFIZER INC.	$24,300	Research payment	In-kind items and services	TALZENNA Drug, ONCOLOGY	FULL TALAZOPARIB AND AVELUMAB IN GENOMICALLY DEFINED METASTATIC RENAL CELL CARCINOMA	2019
2019-12-16	Eisai Inc.	$1,281	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$1,281	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$1,281	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$1,281	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$1,281	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$1,281	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$1,281	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$1,281	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$1,281	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$1,281	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$1,281	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$1,281	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$1,281	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$1,281	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$1,281	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$1,281	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$1,281	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$1,281	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$1,281	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$1,281	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$1,281	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$1,281	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$1,281	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$1,281	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$1,281	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$1,281	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$1,281	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$1,281	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$1,281	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$1,281	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$1,281	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$1,281	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$1,281	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$1,281	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$1,281	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$1,281	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$1,281	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$1,281	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$1,281	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$1,281	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$1,281	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$1,281	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$1,281	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$1,281	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$1,281	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$1,281	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$1,281	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$1,168	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$1,168	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$1,168	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$1,168	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$1,168	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$1,168	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	AstraZeneca Pharmaceuticals LP	$1,000	Grant	Cash or cash equivalent			2019
2019-12-12	Bayer Healthcare Pharmaceuticals Inc.	$172	Research payment	Cash or cash equivalent	Non-Covered	Phase 1 study of Rogaratinib in combination with copanlisib	2019
2019-12-11	PFIZER INC.	$75,411	Research payment	In-kind items and services	BAVENCIO Drug, ONCOLOGY	A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLY	2019
2019-12-10	Bayer Healthcare Pharmaceuticals Inc.	$14,550	Research payment	Cash or cash equivalent	Non-Covered	Ph III Copanlisib+Rituximab in relapsed iNHL	2019
2019-12-09	VENTANA MEDICAL SYSTEMS, INC.	$3,569	Research payment	In-kind items and services	DISCOVERY/SPRING IUO/RUO PLATFORMS & REAGENTS Device, Tissue Diagnostics	RD002198	2019
2019-12-06	Janssen Research & Development, LLC	$815	Research payment	Cash or cash equivalent		A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0)	2019
2019-12-04	Merck Sharp & Dohme LLC	$3,599	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination wit	2019
2019-12-04	Merck Sharp & Dohme LLC	$1,028	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination wit	2019
2019-12-03	EMD Serono, Inc.	$52,453	Research payment	Cash or cash equivalent		MS100036-0020	2019
2019-12-03	EMD Serono, Inc.	$22	Research payment	Cash or cash equivalent	EMD 1214063 Biological, Oncology	MS200095-0022	2019
2019-12-02	Merck Sharp & Dohme LLC	$70,370	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination wit	2019
2019-11-30	EMD Serono, Inc.	$69	Research payment	Cash or cash equivalent	EMD 1214063 Biological, Oncology	MS200095-0022	2019
2019-11-30	EMD Serono, Inc.	$69	Research payment	Cash or cash equivalent	EMD 1214063 Biological, Oncology	MS200095-0022	2019
2019-11-30	EMD Serono, Inc.	$69	Research payment	Cash or cash equivalent	EMD 1214063 Biological, Oncology	MS200095-0022	2019
2019-11-29	VENTANA MEDICAL SYSTEMS, INC.	$3,569	Research payment	In-kind items and services	DISCOVERY/SPRING IUO/RUO PLATFORMS & REAGENTS Device, Tissue Diagnostics	RD002198	2019
2019-11-27	PFIZER INC.	$142,278	Research payment	In-kind items and services	IBRANCE Drug, ONCOLOGY	FULL PHASE III TRIAL OF PALBOCICLIB IN COMBINATION WITH BICALUTAMIDE FOR THE TREATMENT OF AR METASTATIC BREAST CANCER	2019
2019-11-27	PFIZER INC.	$142,278	Research payment	In-kind items and services	IBRANCE Drug, ONCOLOGY	FULL PHASE III TRIAL OF PALBOCICLIB IN COMBINATION WITH BICALUTAMIDE FOR THE TREATMENT OF AR METASTATIC BREAST CANCER	2019
2019-11-25	PFIZER INC.	$100,548	Research payment	In-kind items and services	BAVENCIO Drug, ONCOLOGY	A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLY	2019
2019-11-25	PFIZER INC.	$30,164	Research payment	In-kind items and services	BAVENCIO Drug, ONCOLOGY	A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLY	2019
2019-11-23	Amgen Inc.	$652	Research payment	In-kind items and services		AMG 757_SCLC_20160323	2019
2019-11-22	Merck Sharp & Dohme LLC	$229,929	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	Pilot study of pembrolizumab in untreated extranodal, NK,T cell lymphoma, nasal type SMILE	2019
2019-11-22	EMD Serono, Inc.	$291	Research payment	Cash or cash equivalent	Bavencio Biological, Oncology	MS201943-0029	2019
2019-11-21	PFIZER INC.	$124,000	Research payment	In-kind items and services	VIZIMPRO Drug, ONCOLOGY	A PHASE 2 STUDY OF DACOMITINIB AFTER DISEASE PROGRESSION ON FIRSTLINE OSIMERTINIB IN PATIENTS WITH EGFRMUTANT LUNG CANCE	2019
2019-11-21	Eisai Inc.	$1,168	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-11-14	Bayer Healthcare Pharmaceuticals Inc.	$103,906	Research payment	Cash or cash equivalent	Vitrakvi Drug, Oncology	060205 - Independent Study Support (Bayer Product or TA)	2019
2019-11-13	Cardinal Health 414 LLC	$10,000	Grant	Cash or cash equivalent			2019
2019-11-13	Eisai Inc.	$2,160	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-11-11	PFIZER INC.	$248,000	Research payment	In-kind items and services	VIZIMPRO Drug, ONCOLOGY	PHASE 1 STUDY OF COMBINATION DACOMITINIB AND OSIMERTINIB FOR PATIENTS WITH METASTATIC EGFR MUTANT LUNG CANCERS	2019
2019-11-11	Eisai Inc.	$6,000	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-11-08	Adaptive Biotechnologies Corporation	$172,743	Research payment	Cash or cash equivalent	clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA	15-180	2019
2019-11-08	Adaptive Biotechnologies Corporation	$27,000	Research payment	In-kind items and services	clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA	15-196	2019
2019-11-08	Merck Sharp & Dohme LLC	$10,000	Grant	Cash or cash equivalent			2019
2019-11-05	Eisai Inc.	$13,365	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-11-05	Eisai Inc.	$7,062	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-11-05	Eisai Inc.	$4,320	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-11-05	Eisai Inc.	$1,500	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-11-05	Eisai Inc.	$1,281	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-11-05	Eisai Inc.	$1,281	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-11-05	Eisai Inc.	$1,281	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-11-05	Eisai Inc.	$1,281	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-11-05	Eisai Inc.	$1,281	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-11-05	Eisai Inc.	$1,281	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-11-05	Eisai Inc.	$1,281	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-11-05	Eisai Inc.	$1,281	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-11-05	Eisai Inc.	$1,281	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-11-05	Eisai Inc.	$1,281	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-11-05	Eisai Inc.	$1,281	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-11-05	Eisai Inc.	$1,281	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-11-05	Eisai Inc.	$1,281	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-11-05	Eisai Inc.	$1,168	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-11-05	Eisai Inc.	$1,168	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-11-05	Eisai Inc.	$1,168	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-11-04	PFIZER INC.	$65,356	Research payment	In-kind items and services	BAVENCIO Drug, ONCOLOGY	A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLY	2019
2019-11-04	PFIZER INC.	$30,164	Research payment	In-kind items and services	BAVENCIO Drug, ONCOLOGY	A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLY	2019
2019-11-04	EMD Serono, Inc.	$5,089	Research payment	Cash or cash equivalent	EMD 1214063 Biological, Oncology	MS200095-0022	2019
2019-11-02	Amgen Inc.	$51,943	Research payment	Cash or cash equivalent		AMG 420_Non-Randomized Open-Label Expansion_Multiple Myeloma_20160370.	2019
2019-11-01	EMD Serono, Inc.	$1,300	Research payment	Cash or cash equivalent	Bavencio Biological, Oncology	MS201943-0029	2019
2019-10-31	PFIZER INC.	$248,000	Research payment	In-kind items and services	VIZIMPRO Drug, ONCOLOGY	PHASE 1 STUDY OF COMBINATION DACOMITINIB AND OSIMERTINIB FOR PATIENTS WITH METASTATIC EGFR MUTANT LUNG CANCERS	2019
2019-10-31	Amgen Inc.	$806	Research payment	In-kind items and services		AMG 757_SCLC_20160323	2019
2019-10-31	EMD Serono, Inc.	$69	Research payment	Cash or cash equivalent	EMD 1214063 Biological, Oncology	MS200095-0022	2019
2019-10-31	EMD Serono, Inc.	$69	Research payment	Cash or cash equivalent	EMD 1214063 Biological, Oncology	MS200095-0022	2019
2019-10-31	EMD Serono, Inc.	$69	Research payment	Cash or cash equivalent	EMD 1214063 Biological, Oncology	MS200095-0022	2019
2019-10-30	TESARO, Inc.	$51,852	Research payment	In-kind items and services	ZEJULA Drug, ONCOLOGY	A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENT	2019
2019-10-30	VENTANA MEDICAL SYSTEMS, INC.	$3,569	Research payment	In-kind items and services	DISCOVERY/SPRING IUO/RUO PLATFORMS & REAGENTS Device, Tissue Diagnostics	RD002198	2019
2019-10-28	Boehringer Ingelheim Limited	$2,521	Research payment	In-kind items and services		BI 905677 phase I first-in-man dose finding study	2019
2019-10-28	Plexxikon Inc.	$279	Research payment	Cash or cash equivalent		A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors	2019
2019-10-25	Bayer Healthcare Pharmaceuticals Inc.	$478,594	Research payment	Cash or cash equivalent	Xofigo Drug, Oncology	Start Up Agreement - Prostate Cancer Clinical Trials Consortium LLC The	2019
2019-10-25	Bayer Healthcare Pharmaceuticals Inc.	$200,000	Research payment	Cash or cash equivalent	Xofigo Drug, Oncology	Start Up Agreement - Prostate Cancer Clinical Trials Consortium LLC The	2019
2019-10-25	PFIZER INC.	$97,200	Research payment	In-kind items and services	TALZENNA Drug, ONCOLOGY	FULL TALAZOPARIB AND AVELUMAB IN GENOMICALLY DEFINED METASTATIC RENAL CELL CARCINOMA	2019
2019-10-25	PFIZER INC.	$58,320	Research payment	In-kind items and services	TALZENNA Drug, ONCOLOGY	FULL TALAZOPARIB AND AVELUMAB IN GENOMICALLY DEFINED METASTATIC RENAL CELL CARCINOMA	2019
2019-10-25	Astellas Pharma Global Development	$10,133	Research payment	Cash or cash equivalent	XOSPATA Drug, ONCOLOGY	A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administ	2019
2019-10-23	Merck Sharp & Dohme LLC	$6,000	Grant	Cash or cash equivalent			2019
2019-10-23	Merck Sharp & Dohme LLC	$5,000	Grant	Cash or cash equivalent			2019
2019-10-22	EMD Serono, Inc.	$71,199	Research payment	Cash or cash equivalent		MS100036-0020	2019
2019-10-15	Bayer Healthcare Pharmaceuticals Inc.	$6,150	Research payment	Cash or cash equivalent	Non-Covered	Ph III Copanlisib+Rituximab in relapsed iNHL	2019
2019-10-15	EMD Serono, Inc.	$4,120	Research payment	Cash or cash equivalent	Bavencio Biological, Oncology	MS201943-0029	2019
2019-10-14	PFIZER INC.	$100,548	Research payment	In-kind items and services	BAVENCIO Drug, ONCOLOGY	A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLY	2019
2019-10-14	Merck Sharp & Dohme LLC	$75,783	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination wit	2019
2019-10-14	PFIZER INC.	$30,164	Research payment	In-kind items and services	BAVENCIO Drug, ONCOLOGY	A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLY	2019
2019-10-14	Merck Sharp & Dohme LLC	$4,885	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination wit	2019
2019-10-14	Bayer Healthcare Pharmaceuticals Inc.	$1,759	Research payment	Cash or cash equivalent	Non-Covered	Ph III Copanlisib+Rituximab in relapsed iNHL	2019
2019-10-14	Merck Sharp & Dohme LLC	$1,542	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination wit	2019
2019-10-10	PFIZER INC.	$62,000	Research payment	In-kind items and services	VIZIMPRO Drug, ONCOLOGY	PHASE 1 STUDY OF COMBINATION DACOMITINIB AND OSIMERTINIB FOR PATIENTS WITH METASTATIC EGFR MUTANT LUNG CANCERS	2019
2019-10-10	GE Global Research an unincorporated business of GE Company	$1,144	Research payment	Cash or cash equivalent			2019
2019-10-09	Janssen Research & Development, LLC	$1,606	Research payment	Cash or cash equivalent		A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0)	2019
2019-10-04	Boehringer Ingelheim International GmbH	$47,385	Research payment	Cash or cash equivalent		Empagliflozin and heart failure	2019
2019-10-04	EMD Serono, Inc.	$510	Research payment	Cash or cash equivalent	Bavencio Biological, Oncology	MS201943-0029	2019
2019-10-04	Plexxikon Inc.	$259	Research payment	Cash or cash equivalent		A Study of PLX8394 as a Single Agent in Patients With Advanced, Unresectable Solid Tumors	2019
2019-10-02	PFIZER INC.	$248,000	Research payment	In-kind items and services	VIZIMPRO Drug, ONCOLOGY	PHASE 1 STUDY OF COMBINATION DACOMITINIB AND OSIMERTINIB FOR PATIENTS WITH METASTATIC EGFR MUTANT LUNG CANCERS	2019
2019-10-02	EMD Serono, Inc.	$4,634	Research payment	Cash or cash equivalent	EMD 1214063 Biological, Oncology	MS200095-0022	2019
2019-10-01	Bayer Healthcare Pharmaceuticals Inc.	$83,125	Research payment	Cash or cash equivalent	Vitrakvi Drug, Oncology	060205 - Independent Study Support (Bayer Product or TA)	2019
2019-10-01	EMD Serono, Inc.	$510	Research payment	Cash or cash equivalent	Bavencio Biological, Oncology	MS201943-0029	2019
2019-09-30	EMD Serono, Inc.	$69	Research payment	Cash or cash equivalent	EMD 1214063 Biological, Oncology	MS200095-0022	2019
2019-09-30	EMD Serono, Inc.	$69	Research payment	Cash or cash equivalent	EMD 1214063 Biological, Oncology	MS200095-0022	2019
2019-09-30	EMD Serono, Inc.	$69	Research payment	Cash or cash equivalent	EMD 1214063 Biological, Oncology	MS200095-0022	2019
2019-09-27	VENTANA MEDICAL SYSTEMS, INC.	$3,569	Research payment	In-kind items and services	DISCOVERY/SPRING IUO/RUO PLATFORMS & REAGENTS Device, Tissue Diagnostics	RD002198	2019
2019-09-25	TESARO, Inc.	$51,852	Research payment	In-kind items and services	ZEJULA Drug, ONCOLOGY	A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENT	2019
2019-09-23	AstraZeneca Pharmaceuticals LP	$1,000	Research payment	Cash or cash equivalent	IMFINZI Drug, Oncology	MEDI4736 anti-PD-L1 mab Solid Tumor-MEDI4736 Basket Study (Ph2a)	2019
2019-09-19	Boehringer Ingelheim International GmbH	$7,585	Research payment	Cash or cash equivalent		BAML-16-001-S2/BI 836858 with 5-Aza	2019
2019-09-18	PFIZER INC.	$75,411	Research payment	In-kind items and services	BAVENCIO Drug, ONCOLOGY	A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLY	2019
2019-09-17	Bayer Healthcare Pharmaceuticals Inc.	$38,550	Research payment	Cash or cash equivalent	Non-Covered	Ph III Copanlisib+Rituximab in relapsed iNHL	2019
2019-09-12	Merck Sharp & Dohme LLC	$229,929	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	Phase II study of second-line pembrolizumab plus GVD for relapsed or refractory Hodgkin lymphoma	2019
2019-09-12	Eisai Inc.	$82,755	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-09-12	PFIZER INC.	$59,282	Research payment	In-kind items and services	IBRANCE Drug, ONCOLOGY	FULL PHASE III TRIAL OF PALBOCICLIB IN COMBINATION WITH BICALUTAMIDE FOR THE TREATMENT OF AR METASTATIC BREAST CANCER	2019
2019-09-12	Eisai Inc.	$3,544	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-09-10	PFIZER INC.	$177,848	Research payment	In-kind items and services	IBRANCE Drug, ONCOLOGY	FULL PHASE III TRIAL OF PALBOCICLIB IN COMBINATION WITH BICALUTAMIDE FOR THE TREATMENT OF AR METASTATIC BREAST CANCER	2019
2019-09-10	GE Global Research an unincorporated business of GE Company	$16,702	Research payment	Cash or cash equivalent			2019
2019-09-06	EMD Serono, Inc.	$14,724	Research payment	Cash or cash equivalent	Bavencio Biological, Oncology	MS201943-0029	2019
2019-09-05	Merck Sharp & Dohme LLC	$1,470	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination wit	2019
2019-09-05	AstraZeneca Pharmaceuticals LP	$675	Research payment	Cash or cash equivalent		To assess safety and tolerability describe the dose limiting toxicities determine the maximum tolerated dose MTD or the	2019
2019-09-03	PFIZER INC.	$100,548	Research payment	In-kind items and services	BAVENCIO Drug, ONCOLOGY	A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLY	2019
2019-09-03	AstraZeneca Pharmaceuticals LP	$19,771	Research payment	Cash or cash equivalent		MEDI6383 OX40L FP SOLID TUMOUR MEDI6383 Phase 1 Clinical Trial	2019
2019-09-03	Eisai Inc.	$12,817	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-09-03	Merck Sharp & Dohme LLC	$2,502	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination wit	2019
2019-09-03	EMD Serono, Inc.	$1,367	Research payment	Cash or cash equivalent	EMD 1214063 Biological, Oncology	MS200095-0022	2019
2019-08-31	EMD Serono, Inc.	$69	Research payment	Cash or cash equivalent	EMD 1214063 Biological, Oncology	MS200095-0022	2019
2019-08-31	EMD Serono, Inc.	$69	Research payment	Cash or cash equivalent	EMD 1214063 Biological, Oncology	MS200095-0022	2019
2019-08-31	EMD Serono, Inc.	$69	Research payment	Cash or cash equivalent	EMD 1214063 Biological, Oncology	MS200095-0022	2019
2019-08-29	VENTANA MEDICAL SYSTEMS, INC.	$3,569	Research payment	In-kind items and services	DISCOVERY/SPRING IUO/RUO PLATFORMS & REAGENTS Device, Tissue Diagnostics	RD002198	2019
2019-08-28	Bayer Healthcare Pharmaceuticals Inc.	$518	Research payment	Cash or cash equivalent	Non-Covered	Ph III Copanlisib+Rituximab in relapsed iNHL	2019
2019-08-25	AstraZeneca Pharmaceuticals LP	$25,000	Research payment	Cash or cash equivalent	IMFINZI Drug, Oncology	Durvalumab with Thoracic Radiation Therapy for Locally Advanced Non Small Cell Lung Cancer in Patients Who are Ineligibl	2019
2019-08-21	Merck Sharp & Dohme LLC	$95,499	Research payment	Cash or cash equivalent	KEYTRUDA Biological, ONCOLOGY	A Proof-of-Concept, Pilot Study of Pembrolizumab MK-3475 in Patients with Recurrent Glioblastoma with a Hypermutator Phe	2019

The latest 200 records of 759.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

In New Jersey; placed by its state only.

Measure	State New Jersey
Population B01003	9,343,809
Population, 2020 census P1	9,288,994
Median age B01002	40.1
Under 18 B01001	21.8%
65 and over B01001	17.2%
Households B11001	3,507,701
Foreign born B05002	23.9%
Median household income B19013	$103,556
Median family income B19113	$127,025
Per capita income B19301	$54,253
Poverty rate B17001	9.7%
Unemployment rate B23025	6.3%
Civilian labor force B23025	5,003,179
Mean commute (minutes) B08013	30.5
Bachelor's degree or higher B15003	43.6%
Housing units B25001	3,791,354
Owner-occupied B25003	63.8%
Renters B25003	36.2%
Median home value B25077	$454,400
Median gross rent B25064	$1,720
White, not Hispanic B03002	50.9%
Black B03002	12.2%
Hispanic or Latino B03002	22.5%
Asian B03002	10.0%
American Indian and Alaska Native B03002	0.1%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in New Jersey.